WO2001089550A3 - Use of ciliary neurotrophic factor - Google Patents

Use of ciliary neurotrophic factor Download PDF

Info

Publication number
WO2001089550A3
WO2001089550A3 PCT/US2001/040783 US0140783W WO0189550A3 WO 2001089550 A3 WO2001089550 A3 WO 2001089550A3 US 0140783 W US0140783 W US 0140783W WO 0189550 A3 WO0189550 A3 WO 0189550A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotrophic factor
ciliary neurotrophic
gestational
intranasal
obesity
Prior art date
Application number
PCT/US2001/040783
Other languages
French (fr)
Other versions
WO2001089550A2 (en
Inventor
Vivien W Wong
Ellen M Koehler-Stec
Neil Stahl
Original Assignee
Regeneron Pharma
Vivien W Wong
Ellen M Koehler-Stec
Neil Stahl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/577,468 external-priority patent/US6767894B1/en
Application filed by Regeneron Pharma, Vivien W Wong, Ellen M Koehler-Stec, Neil Stahl filed Critical Regeneron Pharma
Priority to AU2001263514A priority Critical patent/AU2001263514A1/en
Priority to CA002409956A priority patent/CA2409956A1/en
Priority to EP01937817A priority patent/EP1365785A2/en
Priority to JP2001585793A priority patent/JP2003535831A/en
Publication of WO2001089550A2 publication Critical patent/WO2001089550A2/en
Publication of WO2001089550A3 publication Critical patent/WO2001089550A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Lock And Its Accessories (AREA)

Abstract

Compositions and methods for the intranasal or respiratory administration of ciliary neurotrophic factor proteins, especially in the treatment of obesity and gestational or adult onset diabetes.
PCT/US2001/040783 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor WO2001089550A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001263514A AU2001263514A1 (en) 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor
CA002409956A CA2409956A1 (en) 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor
EP01937817A EP1365785A2 (en) 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor
JP2001585793A JP2003535831A (en) 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/577,468 US6767894B1 (en) 1998-02-27 2000-05-24 Use of ciliary neurotrophic factor
US09/577,468 2000-05-24

Publications (2)

Publication Number Publication Date
WO2001089550A2 WO2001089550A2 (en) 2001-11-29
WO2001089550A3 true WO2001089550A3 (en) 2003-07-10

Family

ID=24308868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040783 WO2001089550A2 (en) 2000-05-24 2001-05-22 Use of ciliary neurotrophic factor

Country Status (5)

Country Link
EP (1) EP1365785A2 (en)
JP (1) JP2003535831A (en)
AU (1) AU2001263514A1 (en)
CA (1) CA2409956A1 (en)
WO (1) WO2001089550A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053728A2 (en) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Obesity-associated proteins and the use thereof in therapy and diagnosis
WO2006017156A2 (en) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Methods for identifying a candidate for treatment of obesity
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
CN107073077B (en) * 2014-11-07 2020-12-01 陕西麦科奥特科技有限公司 Ciliary neurotrophic factor nasal administration system and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004316A2 (en) * 1989-09-15 1991-04-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ciliary neurotrophic factor
WO1991019009A1 (en) * 1990-06-01 1991-12-12 Regeneron Pharmaceuticals, Inc. The ciliary neurotrophic factor receptor
WO1998022128A1 (en) * 1996-11-19 1998-05-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
EP1010432A1 (en) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004316A2 (en) * 1989-09-15 1991-04-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ciliary neurotrophic factor
WO1991019009A1 (en) * 1990-06-01 1991-12-12 Regeneron Pharmaceuticals, Inc. The ciliary neurotrophic factor receptor
WO1998022128A1 (en) * 1996-11-19 1998-05-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
EP1010432A1 (en) * 1997-01-23 2000-06-21 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLOAGUEN I ET AL: "Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 JUN 10) 94 (12) 6456-61., XP002216008 *
MILLER, R. G. (1) ET AL: "Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.", NEUROLOGY, (1996) VOL. 47, NO. 5, PP. 1329-1331., XP001064801 *
MILLER, ROBERT G. (1) ET AL: "A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis.", ANNALS OF NEUROLOGY, (1996) VOL. 39, NO. 2, PP. 256-260., XP008005507 *

Also Published As

Publication number Publication date
WO2001089550A2 (en) 2001-11-29
CA2409956A1 (en) 2001-11-29
AU2001263514A1 (en) 2001-12-03
EP1365785A2 (en) 2003-12-03
JP2003535831A (en) 2003-12-02

Similar Documents

Publication Publication Date Title
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
NZ506267A (en) Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2002094200A3 (en) Pulmonary administration of chemically modified insulin
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
WO2001062290A3 (en) Methods and compositions for improving sleep
HK1046845A1 (en) Vibrator for lower limbs, and chair type vibrator using the vibrator.
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
HK1099273A1 (en) Process for the preparation of 1,1,1,3,3,3-hexafluoropropane and at least one of 1,1,1,2,3,3-hexafluoropropane and 1,1,1,2,3,3,3-heptafluoropropane
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2005018605A3 (en) Novel formulation of ropinirole
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
IS6874A (en) 3,7-diazabicyclo [3.3.0] octane and its use in the treatment of arrhythmias
AU2001242130A1 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
WO2001089550A3 (en) Use of ciliary neurotrophic factor
PL1689410T3 (en) Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2002087604A3 (en) Preparations containing a combination of vitamin e and afamin
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2409956

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001263514

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001937817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937817

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001937817

Country of ref document: EP